Most pediatric patients with essential thrombocythemia show hypersensitivity to erythropoietin in vitro, with rare JAK2 V617F-positive erythroid colonies

Leukemia Research

Volumn 32, Issue 3, 2008, Pages 369-377

  Veselovska, Jitka ^a   Pospisilova, Dagmar ^a   Pekova, Sona ^b   Horvathova, Monika ^a   Solna, Renata ^a   Cmejlova, Jana ^c   Cmejla, Radek ^c   Belickova, Monika ^c   Mihal, Vladimir ^a   Stary, Jan ^d   Divoky, Vladimir ^a  

^a PALACKÝ UNIVERSITY   (Czech Republic)

^b NA HOMOLCE HOSPITAL   (Czech Republic)

^c INSTITUTE OF HEMATOLOGY AND BLOOD TRANSFUSION   (Czech Republic)

^d UNIVERSITY HOSPITAL MOTOL   (Czech Republic)

Author keywords

Childhood ET; Clonality; Epo hypersensitivity; JAK2 V617F mutation

Indexed keywords

ERYTHROPOIETIN; JANUS KINASE 2;

ADOLESCENT; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; ERYTHROID CELL; FEMALE; GENE MUTATION; GRANULOCYTE; HUMAN; HYPERSENSITIVITY; IN VITRO STUDY; MALE; MOLECULAR CLONING; PHILADELPHIA 1 CHROMOSOME; PRESCHOOL CHILD; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SCHOOL CHILD; THROMBOCYTE; THROMBOCYTHEMIA; THROMBOCYTOSIS;

ADOLESCENT; CHILD; CLONE CELLS; ERYTHROID PROGENITOR CELLS; ERYTHROPOIESIS; ERYTHROPOIETIN; FEMALE; GENOTYPE; HEMATOPOIETIC STEM CELLS; HUMANS; JANUS KINASE 2; MALE; MUTATION; THROMBOCYTHEMIA, HEMORRHAGIC; THROMBOCYTOSIS;

EID: 39749127371     PISSN: 01452126     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.leukres.2007.07.011     Document Type: Article

References (27)

1. Dame Ch, and Sutor A.H. Primary and secondary thrombocytosis in childhood. Br J Haematol 129 (2005) 165-177
2. Kralovics R., and Skoda R.C. Molecular pathogenesis of Philadelphia chromosome negative myeloproliferative disorders. Blood Rev 19 (2005) 1-13
3. Kralovics R., Passamonti F., Buser A.S., Teo S.S., Tiedt R., Passweg J.R., et al. A gain-of-function mutation of JAK2 in myeloproliferative disorders. N Engl J Med 352 (2005) 1779-1790
4. Baxter E.J., Scott L.M., Campbell P.J., East C., Fourouclas N., Swanton S., et al. Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders. Lancet 365 (2005) 1054-1061
5. Levine R.L., Wadleigh M., Cools J., Ebert B.L., Wernig G., Huntly B.J., et al. Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis. Cancer Cell 7 (2005) 387-397
6. Lippert E., Boissinot M., Kralovics R., Girodon F., Dobo I., Praloran V., et al. The JAK2-V617F mutation is frequently present at diagnosis in patients with essential thrombocythemia and polycythemia vera. Blood 108 (2006) 1865-1867
7. Kralovics R., Teo S.S., Li S., Theocharides A., Buser A.S., Tichelli A., et al. Acquisition of the V617F mutation of JAK2 is a late genetic event in a subset of patients with myeloproliferative disorders. Blood 108 (2006) 1377-1380
8. Nussenzveig R.H., Swierczek S.I., Jelinek J., Gaikwad A., Liu E., Verstovsek S., et al. Polycythemia vera is not initiated by JAK2V617F mutation. Exp Hematol 35 (2007) 32-38
9. El-Kassar N., Hetet G., Briere J., and Grandchamp B. Clonality analysis of hematopoiesis and thrombopoietin levels in patients with essential thrombocythemia. Leuk Lymphoma 30 (1998) 181-188
10. Randi M.L., Putti M.C., Scapin M., Pacquola E., Tucci F., Micalizzi C., et al. Pediatric patients with essential thrombocythemia are mostly polyclonal and V617FJAK2 negative. Blood 108 (2006) 3600-3602
11. Murphy S., Peterson P., Iland H., and Laszlo J. Experience of the polycythemia vera study group with essential thrombocythemia: a final report of diagnostic criteria, survival and leukemic transition by treatment. Semin Hematol 34 (1997) 29-39
12. Zadrazil J., Horak P., Horcicka V., Zahalkova J., Strebl P., and Hruby M. Endogenous erythropoietin levels and anemia in long-term renal transplant recipients. Kidney Blood Press Res 30 (2007) 108-116
13. Ishiguro A., Nakahata T., Matsubara K., Hayashi Y., Kato T., and Suzuki Y. Age-related changes in thrombopoietin in children: reference interval for serum thrombopoietin levels. Br J Haematol 106 (1999) 884-888
14. Pospisilova D., Cmejlova J., Slavik L., and Cmejla R. Elevated thrombopoietin levels and alterations in the sequence of its receptor c-Mpl in patients with Diamond-Blackfan anaemia. Haematologica 89 (2004) 1391-1392
15. Prchal J.T., and Sokol L. Benign erythrocytosis and other familial and congenital polycythaemias. Eur J Haematol 57 (1996) 263-268
16. Prchal J.T., Throckmorton D.W., Carroll III A.J., Fuson E.W., Gams R.A., and Prchal J.F. A common progenitor for human myeloid and lymphoid cells. Nature 274 (1978) 590-591
17. Campbell P.J., Scott L.M., Buck G., Wheatley K., East C.L., Marsden J.T., et al. Definition of subtypes of essential thrombocythaemia and relation to polycythaemia vera based on JAK2 V617F mutation status: a prospective study. Lancet 366 (2005) 1945-1953
18. Cermak J., Belickova M., Krejcova H., Michalova K., Zilovcova S., Zemanova Z., et al. The presence of clonal cell subpopulations in peripheral blood and bone marrow of patients with refractory cytopenia with multilineage dysplasia but not in patients with refractory anemia may reflect a multistep pathogenesis of myelodysplasia. Leuk Res 29 (2005) 371-379
19. Shih L.Y., and Lee C.T. Identification of masked polycythemia vera from patients with idiopathic marked thrombocytosis by endogenous erythroid colony assay. Blood 83 (1994) 744-748
20. Dupont S., Masse A., James C., Teyssandier I., Lecluse Y., Larbret F., et al. The JAK2 V617F mutation triggers erythropoietin hypersensitivity and terminal erythroid amplification in primary cells from patients with polycythemia vera. Blood 110 (2007) 1013-1021
21. Pospisilova D, Mihal V, Votava T, Hak J, Ptoszkova H, Blatny J, et al. Essential thrombocythemia in children in the Czech Republic. Leuk Res 2006;30(Suppl 2):S1 (abstract).
22. Bellanne-Chantelot C., Chaumarel I., Labopin M., Bellanger F., Barbu V., De Toma V., et al. Genetic and clinical implications of the Val617Phe JAK2 mutation in 72 families with myeloproliferative disorders. Blood 108 (2006) 346-352
23. Rumi E., Passamonti F., Pietra D., Della Porta M.G., Arcaini L., Boggi S., et al. JAK2 (V617F) as an acquired somatic mutation and a secondary genetic event associated with disease progression in familial myeloproliferative disorders. Cancer 107 (2006) 2206-2211
24. Scott L.M., Scott M.A., Campbell P.J., and Green A.R. Progenitors homozygous for the V617F mutation occur in most patients with polycythemia vera, but not essential thrombocythemia. Blood 108 (2006) 2435-2437
25. Antonioli E., Guglielmelli P., Pancrazzi P., Bogani C., Verrucci M., Ponziani V., et al. Clinical implications of the JAK2 V617F mutation in essential thrombocythemia. Leukemia 19 (2005) 1847-1849
26. Vannucchi A.M., Antonioli E., Guglielmelli P., Rambaldi A., Barosi G., Marchioli R., et al. Clinical profile of homozygous JAK2V617F mutation in patients with polycythemia vera or essential thrombocythemia. Blood 110 (2007) 840-846
27. Campbell P.J., Baxter E.J., Beer P.A., Scott L.M., Bench A.J., Huntly B.J., et al. Mutation of JAK2 in the myeloproliferative disorders: timing, clonality studies, cytogenetic associations and role in leukemic transformation. Blood 108 (2006) 3548-3555